Estimating efficacy in trials with selective crossover. - Wikidata - wikimedia - TriplyDB

Estimating efficacy in trials with selective crossover.

Estimating efficacy in trials with selective crossover.

http://www.wikidata.org/entity/Q33835695

about

Estimating efficacy in trials with selective crossover.

http://www.wikidata.org/entity/Q33835695

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Estimating efficacy in trials with selective crossover.

@ast

Estimating efficacy in trials with selective crossover.

@en

type

label

Estimating efficacy in trials with selective crossover.

@ast

Estimating efficacy in trials with selective crossover.

@en

prefLabel

Estimating efficacy in trials with selective crossover.

@ast

Estimating efficacy in trials with selective crossover.

@en

P1433

Q33835695-3D330176-BD5F-442A-B6EA-F119E2B1AD70

P1476

Q33835695-675C3FEF-A800-43BB-957F-65C45512BC73

P2093

Q33835695-946EA060-CD82-4798-86BC-50ACC433D51E

P2860

Q33835695-067C289E-34DD-44D1-A145-1EE940B5F0AC

Q33835695-1EB6AB39-BDE4-4F11-861D-E992BC32A014

Q33835695-23E961E0-1205-41D6-9483-45BF8DBE9D15

Q33835695-26ACA103-DC41-4900-A032-674589F158A2

Q33835695-3CDE109B-C9A8-4FE2-BB17-DB39BF525D20

Q33835695-42B9E684-D485-42C9-BF55-993D30CBB14D

Q33835695-43CE3825-C59B-4A94-AC54-052A3DEDD60E

Q33835695-4A665E35-F5A9-4235-A05B-5BC55A381AFA

Q33835695-549A84A3-B408-4011-A9F9-850B6E2EDF0D

Q33835695-60612FD3-4834-4383-8B04-7D0E91B1D58D

P304

Q33835695-8E6D1521-3FEF-422A-BA7F-EA1DB39E1EBC

P31

Q33835695-65A5B1FB-792E-4295-A30D-BDB3A3E6ED87

P356

Q33835695-123E253F-0EFA-426D-89F9-502E10DB1EB1

P407

Q33835695-E79ED4FB-9F0D-49DC-B65E-1783EC368954

P433

Q33835695-C01B6EAF-4459-4C4C-98CA-C5A450AF57CE

P478

Q33835695-A565A726-FC1C-49F3-A773-DD78B7FB94C1

P50

Q33835695-09A5BD55-BE81-465B-B195-8E36692CDE28

Q33835695-56E9AD02-17F0-42B6-BFAC-0F0B46BA49CA

P577

Q33835695-0B21F04C-9C69-4E6D-A1FA-6DEA2FAF66A4

P698

Q33835695-0A5F0C13-4BE9-4B60-8929-8DE682FE830C

P932

Q33835695-53CE79BF-A53E-4616-8909-001F408709A5

P356

P1433

Statistics in Medicine

P1476

Estimating efficacy in trials with selective crossover.

@en

P2093

Jack Cuzick

http://www.w3.org/2001/XMLSchema#string

P2860

On estimating efficacy from clinical trials.

Principal stratification in causal inference

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.

Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.

Weighting in instrumental variables and G-estimation.

Parametric randomization-based methods for correcting for treatment changes in the assessment of the causal effect of treatment.

P304

2333-2346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/SIM.7275

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Adam R Brentnall

P577

2017-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28295486

http://www.w3.org/2001/XMLSchema#string

P932

5485026

http://www.w3.org/2001/XMLSchema#string